Luke Sergott
Stock Analyst at Barclays
(2.38)
# 1,448
Out of 4,479 analysts
182
Total ratings
45.96%
Success rate
-3.68%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Underweight | $295 → $275 | $284.49 | -3.34% | 13 | Jun 28, 2024 | |
| TMO Thermo Fisher | Maintains: Equal-Weight | $615 → $600 | $533.93 | +12.37% | 21 | Jun 28, 2024 | |
| RVTY Revvity | Maintains: Equal-Weight | $116 → $115 | $102.01 | +12.73% | 4 | Jun 28, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $275 → $255 | $207.47 | +22.91% | 15 | Jun 28, 2024 | |
| CERT Certara | Maintains: Equal-Weight | $18 → $16 | $13.66 | +17.13% | 11 | Jun 28, 2024 | |
| AVTR Avantor | Maintains: Overweight | $28 → $25 | $20.58 | +21.48% | 18 | Jun 28, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $36 → $24 | $18.87 | +27.19% | 6 | Jun 28, 2024 | |
| A Agilent Technologies | Maintains: Underweight | $135 → $125 | $125.78 | -0.62% | 3 | May 31, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $3 → $2 | $1.28 | +56.25% | 4 | May 10, 2024 | |
| TWST Twist Bioscience | Maintains: Overweight | $40 → $45 | $47.32 | -4.90% | 13 | May 3, 2024 | |
| DHR Danaher | Maintains: Equal-Weight | $260 → $270 | $240.41 | +12.31% | 18 | Apr 24, 2024 | |
| ILMN Illumina | Maintains: Underweight | $85 → $100 | $105.51 | -5.22% | 11 | Apr 10, 2024 | |
| SHC Sotera Health Company | Maintains: Overweight | $19 → $14 | $11.63 | +20.38% | 14 | Apr 10, 2024 | |
| ICLR ICON PLC | Maintains: Overweight | $325 → $355 | $318.30 | +11.53% | 12 | Feb 23, 2024 | |
| FTRE Fortrea Holdings | Maintains: Overweight | $38 → $35 | $23.80 | +47.06% | 3 | Jan 25, 2024 | |
| CTLT Catalent | Maintains: Equal-Weight | $45 → $47 | $56.20 | -16.37% | 15 | Jan 25, 2024 | |
| CNTG Centogene | Downgrades: In-Line | n/a | $0.41 | - | 1 | Apr 24, 2020 |
Waters
Jun 28, 2024
Maintains: Underweight
Price Target: $295 → $275
Current: $284.49
Upside: -3.34%
Thermo Fisher
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $615 → $600
Current: $533.93
Upside: +12.37%
Revvity
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $116 → $115
Current: $102.01
Upside: +12.73%
IQVIA Holdings
Jun 28, 2024
Maintains: Overweight
Price Target: $275 → $255
Current: $207.47
Upside: +22.91%
Certara
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $13.66
Upside: +17.13%
Avantor
Jun 28, 2024
Maintains: Overweight
Price Target: $28 → $25
Current: $20.58
Upside: +21.48%
10x Genomics
Jun 28, 2024
Maintains: Overweight
Price Target: $36 → $24
Current: $18.87
Upside: +27.19%
Agilent Technologies
May 31, 2024
Maintains: Underweight
Price Target: $135 → $125
Current: $125.78
Upside: -0.62%
Pacific Biosciences of California
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.28
Upside: +56.25%
Twist Bioscience
May 3, 2024
Maintains: Overweight
Price Target: $40 → $45
Current: $47.32
Upside: -4.90%
Danaher
Apr 24, 2024
Maintains: Equal-Weight
Price Target: $260 → $270
Current: $240.41
Upside: +12.31%
Illumina
Apr 10, 2024
Maintains: Underweight
Price Target: $85 → $100
Current: $105.51
Upside: -5.22%
Sotera Health Company
Apr 10, 2024
Maintains: Overweight
Price Target: $19 → $14
Current: $11.63
Upside: +20.38%
ICON PLC
Feb 23, 2024
Maintains: Overweight
Price Target: $325 → $355
Current: $318.30
Upside: +11.53%
Fortrea Holdings
Jan 25, 2024
Maintains: Overweight
Price Target: $38 → $35
Current: $23.80
Upside: +47.06%
Catalent
Jan 25, 2024
Maintains: Equal-Weight
Price Target: $45 → $47
Current: $56.20
Upside: -16.37%
Centogene
Apr 24, 2020
Downgrades: In-Line
Price Target: n/a
Current: $0.41
Upside: -